Hoth Therapeutics Expands HT-001 Phase 2a Trial for EGFRi-Induced Skin Toxicities
Key Insights
Hoth Therapeutics has received IRB approval from Montefiore Medical Center and Dana-Farber Cancer Institute for its Phase 2a trial of HT-001.
The Phase 2a trial will assess the efficacy, safety, and tolerability of topical HT-001 for skin toxicities (search) related to EGFR inhibitor treatments.
This First-in-Human trial aims to provide a new therapeutic option for cancer patients suffering from EGFRi (search)-associated skin toxicities (search).
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced the expansion of its Phase 2a clinical trial for HT-001, a novel therapeutic being developed to treat skin toxicities (search) associated with Epidermal Growth Factor Receptor Inhibitors (search) (EGFRi (search)). The company has received Institutional Review Board (IRB) approval from Montefiore Medical Center in New York, NY, and the Dana-Farber Cancer Institute in Boston, MA, allowing these institutions to participate as clinical sites.
The Phase 2a trial is designed as a First-in-Human (FIH), dose-ranging study to evaluate the efficacy, safety, and tolerability of topical HT-001 in patients experiencing skin toxicities (search) resulting from EGFRi (search) treatments. EGFR inhibitors are commonly used in cancer therapy, but often lead to debilitating skin-related side effects, impacting patients' quality of life.
Trial Objectives and Design
The study will primarily focus on assessing the safety profile of HT-001 and determining the optimal dosage range. Secondary endpoints include evaluating the drug's efficacy in reducing the severity and duration of skin toxicities (search). The trial will enroll patients who have developed skin toxicities as a result of EGFRi (search) therapy. Further details about the trial design and inclusion/exclusion criteria can be found on clinicaltrials.gov.
Management Commentary
"We are very pleased to have received approval from these two world class medical centers for our FIH clinical trial," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "We are hopeful that this trial will demonstrate successful delivery of our lead therapeutic candidate HT-001 and bring hope to cancer patients suffering from skin toxicities (search) associated with EGFRi (search) treatments."
Financial Position
In addition to the clinical trial update, Hoth Therapeutics reported a solid financial position, with over $9 million in cash reserves at the end of the prior quarter. The company has stated that it does not anticipate any further capital raises in 2024, providing financial stability for ongoing research and development activities.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a biopharmaceutical company focused on developing innovative treatments to improve patient quality of life. The company is dedicated to advancing early-stage pharmaceutical research and development, with a patient-centric approach to identify and investigate therapeutics with breakthrough potential.